Hepcidin levels in Diamond-Blackfan anemia reflect erythropoietic activity and transfusion dependency

Haematologica

Volumn 99, Issue 7, 2014, Pages

  Pospisilova, Dagmar ^a   Holub, Dusan ^a   Zidova, Zuzana ^a   Sulovska, Lucie ^a   Houda, Jiri ^a   Mihal, Vladimir ^a   Hadacova, Ivana ^b   Radova, Lenka ^c   Dzubak, Petr ^a   Hajduch, Marian ^a   Divoky, Vladimir ^a   Horvathova, Monika ^a  

^a PALACKÝ UNIVERSITY   (Czech Republic)

^b CHARLES UNIVERSITY   (Czech Republic)

^c MASARYK UNIVERSITY   (Czech Republic)

Author keywords

Diamond Blackfan anemia; Erythropoietic activity; Hepcidin levels; Transfusion dependency

Indexed keywords

CORTICOSTEROID; ERYTHROPOIETIN; FERRITIN; GROWTH DIFFERENTIATION FACTOR 15; HEPCIDIN; LEUCINE; RIBOSOME PROTEIN; STEROID; TRANSFERRIN RECEPTOR;

ADOLESCENT; ADULT; BETA THALASSEMIA; BLACKFAN DIAMOND ANEMIA; BLOOD TRANSFUSION; CHELATION THERAPY; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; ERYTHROBLAST; ERYTHROPOIESIS; GENE MUTATION; HUMAN; HUMAN TISSUE; IRON BLOOD LEVEL; IRON METABOLISM; KUPFFER CELL; LETTER; LIVER BIOPSY; LIVER CELL; REMISSION; ANEMIA, DIAMOND-BLACKFAN; BLOOD; PROGNOSIS;

ANEMIA, DIAMOND-BLACKFAN; BLOOD TRANSFUSION; ERYTHROPOIESIS; HEPCIDINS; HUMANS; PROGNOSIS;

EID: 84903594264     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2014.104034     Document Type: Letter

References (15)

1. Boria I, Garelli E, Gazda HT, Aspesi A, Quarello P, Pavesi E, et al. The ribosomal basis of Diamond-Blackfan Anemia: mutation and database update. Hum Mutat. 2010;31(12):1269-79.
2. Vlachos A, Ball S, Dahl N, Alter BP, Sheth S, Ramenghi U, et al. Diagnosing and treating Diamond Blackfan anaemia: results of an international clinical consensus conference. Br J Haematol. 2008;142(6):859-76.
3. Tanno T, Noel P, Miller JL. Growth differentiation factor 15 in erythroid health and disease. Curr Opin Hematol. 2010;17(3):184-90.
4. Origa R, Galanello R, Ganz T, Giagu N, Maccioni L, Faa G, et al. Liver iron concentrations and urinary hepcidin in beta-thalassemia. Haematologica. 2007;92(5):583-8.
5. Mojzikova R, Koralkova P, Holub D, Zidova Z, Pospisilova D, Cermak J, et al. Iron status in patients with pyruvate kinase deficiency: neonatal hyperferritinaemia associated with a novel frameshift deletion in the PKLR gene (p. Arg518fs), and low hepcidin to ferritin ratios. Br J Haematol. 2014;165(4):556-63.
6. Pospisilova D, Cmejlova J, Ludikova B, Stary J, Cerna Z, Hak J, et al. The Czech National Diamond-Blackfan Anemia Registry: clinical data and ribosomal protein mutations update. Blood Cells Mol Dis. 2012;48(4):209-18.
7. Pospisilova D, Cmejlova J, Hak J, Adam T, Cmejla R. Successful treatment of a Diamond-Blackfan anemia patient with amino acid leucine. Haematologica. 2007;92(5):e66-7.
8. Ganz T, Nemeth E. Hepcidin and iron homeostasis. Biochim Biophys Acta. 2012;1823(9):1434-43.
9. Hentze MW, Muckenthaler MU, Galy B, Camaschella C. Two to tango: regulation of mammalian iron metabolism. Cell. 2010;142 (1):24-38.
10. Brissot P, Ropert M, Le Lan C, Loréal O. Non-transferrin bound iron: a key role in iron overload and iron toxicity. Biochim Biophys Acta. 2012;1820(3):403-10.
11. Hoffbrand AV, Taher A, Cappellini MD. How I treat transfusional iron overload. Blood. 2012;120(18):3657-69.
12. Berdoukas V, Nord A, Carson S, Puliyel M, Hofstra T, Wood J, et al. Tissue iron evaluation in chronically transfused children shows significant levels of iron loading at a very young age. Am J Hematol. 2013;88(11):E283-5.
13. van Dijk BA, Laarakkers CM, Klaver SM, Jacobs EM, van Tits LJ, Janssen MC, et al. Serum hepcidin levels are innately low in HFErelated haemochromatosis but differ between C282Y-homozygotes with elevated and normal ferritin levels. Br J Haematol. 2008;142(6):979-85.
14. Vokurka M, Krijt J, Sulc K, Necas E. Hepcidin mRNA levels in mouse liver respond to inhibition of erythropoiesis. Physiol Res. 2006;55(6):667-74.
15. Pak M, Lopez MA, Gabayan V, Ganz T, Rivera S. Suppression of hepcidin during anemia requires erythropoietic activity. Blood. 2006;108(12):3730-5.